29211-44-7

Basic information

• Product Name: Ethyl (5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)acetate
• Synonyms: Ethyl (5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)acetate;2-(5-keto-1-phenyl-4H-pyrazol-3-yl)acetic acid ethyl ester;2-(5-oxo-1-phenyl-4H-pyrazol-3-yl)acetic acid ethyl ester;ethyl 2-(5-oxo-1-phenyl-4H-pyrazol-3-yl)acetate;ethyl 2-(5-oxo-1-phenyl-4H-pyrazol-3-yl)ethanoate;MLS000676260;SMR000272002;ZINC00473003
• CAS NO: 29211-44-7
• Molecular Formula: C₁₃H₁₄N₂O₃
• Molecular Weight: 246.26186
• Mol File: 29211-44-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethyl (5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl (5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)acetate(29211-44-7)
• EPA Substance Registry System: Ethyl (5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)acetate(29211-44-7)

Safety Data

• Hazardous Substances Data: 29211-44-7(Hazardous Substances Data)

Upstream product

• 100-63-0 phenylhydrazine 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 

Relevant articles and documents

Diversity-Oriented Synthesis of Spiropentadiene Pyrazolones and 1 H-Oxepino[2,3- c]pyrazoles from Doubly Conjugated Pyrazolones via Intramolecular Wittig Reaction

An efficient method for the diversity-oriented synthesis of spiropentadiene pyrazolones and 1H-oxepino[2,3-c]pyrazoles is reported. The methodology attributes O-acylation of phosphorus zwitterions which were formed by a tandem phospha-1,6-addition of PBu3 to α,β,γ,δ-unsaturated pyrazolones, further generating betaine intermediates that preferentially resulted in the aforementioned cyclic products in a diversity-oriented manner. The mechanistic investigations revealed that formation of the betaines is the key step to provide the products via an intramolecular Wittig reaction or an unprecedented δ-C-acylation/cyclization/Wittig reaction.

DRUGS COMPRISING COMBINATION OF ANTITHROMBOTIC AGENT WITH PYRAZOLONE DERIVATIVE

It is intended to provide drugs for treating and/or preventing ischemic diseases which are safe and have little side effects. Namely, drugs comprising a combination of an antithrombotic agent and a pyrazolone derivative defined in the description or its pharmaceutically acceptable salt.